{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:16:27Z","timestamp":1787836587502,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008376","name":"Helsingin ja uudenmaan sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.msard.2023.105134","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T16:55:40Z","timestamp":1699721740000},"page":"105134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Frequency and risk factors of rebound after fingolimod discontinuation \u2013 A retrospective study"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-0554","authenticated-orcid":false,"given":"A","family":"Maunula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Atula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PJ","family":"Tienari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2023.105134_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study","volume":"9","author":"Claes","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2023.105134_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228380","article-title":"Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets","volume":"15","author":"Hjorth","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.msard.2023.105134_bib0003","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.105134_bib0004","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40261-019-00804-6","article-title":"Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod","volume":"39","author":"Fragoso","year":"2019","journal-title":"Clin. Drug. Investig."},{"issue":"5","key":"10.1016\/j.msard.2023.105134_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1756285615594575","article-title":"Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment","volume":"8","author":"Faissner","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.105134_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2018.07.001","article-title":"Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases","volume":"25","author":"S\u00e1nchez","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105134_bib0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"issue":"17","key":"10.1016\/j.msard.2023.105134_bib0008","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2023.105134_bib0009","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.105134_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101483","article-title":"Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors","volume":"38","author":"Sep\u00falveda","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105134_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103278","article-title":"Factors associated with fingolimod rebound: a single center real-life experience","volume":"56","author":"Goncuoglu","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105134_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329607","article-title":"Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark","author":"Framke","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.105134_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102918","article-title":"Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment","volume":"51","author":"Pantazou","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105134_bib0014","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-021-10658-8","article-title":"What happens after fingolimod discontinuation? A multicentre real-life experience","volume":"269","author":"Landi","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105134_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103329","article-title":"Rebound activity after fingolimod cessation: a case - control study","volume":"57","author":"Barboza","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105134_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221150312","article-title":"Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis","volume":"16","author":"Cerd\u00e1-Fuertes","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.105134_bib0017","first-page":"700","article-title":"The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis","volume":"126","author":"Demirci","year":"2016","journal-title":"Int. J. Neurosci."},{"issue":"4","key":"10.1016\/j.msard.2023.105134_bib0018","article-title":"The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis","volume":"4","author":"Hasselbalch","year":"2018","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"issue":"2","key":"10.1016\/j.msard.2023.105134_bib0019","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00415-020-10322-7","article-title":"Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?","volume":"268","author":"Gelibter","year":"2021","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.105134_bib0020","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cells8101114","article-title":"The neutrophil-to-Lymphocyte ratio is related to disease activity in relapsing remitting multiple sclerosis","volume":"8","author":"D'Amico","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.msard.2023.105134_bib0021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ane.13145","article-title":"Multiple sclerosis in Finland 2018-data from the national register","volume":"140","author":"Laakso","year":"2019","journal-title":"Acta Neurol. Scand."},{"issue":"18","key":"10.1016\/j.msard.2023.105134_bib0022","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2169\/internalmedicine.0793-18","article-title":"Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis","volume":"57","author":"Sato","year":"2018","journal-title":"Intern. Med. Tokyo Jpn."},{"issue":"4","key":"10.1016\/j.msard.2023.105134_bib0023","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40261-022-01129-7","article-title":"Multiple sclerosis relapses following cessation of Fingolimod","volume":"42","author":"Malpas","year":"2022","journal-title":"Clin. Drug. Investig."},{"issue":"12","key":"10.1016\/j.msard.2023.105134_bib0024","first-page":"1330","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis","volume":"93","author":"Zhu","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.105134_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105134_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103076","article-title":"How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP)","volume":"53","author":"Bigaut","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.105134_bib0027","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/1352458518763095","article-title":"Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation","volume":"24","author":"Giordana","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105134_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:02:28Z","timestamp":1719968548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823006351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"alternative-id":["S2211034823006351"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105134","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency and risk factors of rebound after fingolimod discontinuation \u2013 A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105134"}}